RPRX Quote, Financials, Valuation and Earnings

Cytokinetics, Inc. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of -1030.87%. Royalty Pharma Plc's return on equity of 13.52% beat Cytokinetics, Inc.'s return on equity of --.

Royalty Pharma Plc has a consensus price target of $51.56, signalling upside risk potential of 8.95%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $92.82 which suggests that it could grow by 42.94%. Given that Cytokinetics, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Cytokinetics, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.395, which suggesting that the stock is 60.476% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.551%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are larger than Cytokinetics, Inc. quarterly revenues of $17.8M. Royalty Pharma Plc's net income of $356M is higher than Cytokinetics, Inc.'s net income of -$183M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.88x while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.31x versus 88.58x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of 20.83%. Royalty Pharma Plc's return on equity of 13.52% beat Johnson & Johnson's return on equity of 34.46%.

Royalty Pharma Plc has a consensus price target of $51.56, signalling upside risk potential of 8.95%. On the other hand Johnson & Johnson has an analysts' consensus of $241.08 which suggests that it could grow by 0.05%. Given that Royalty Pharma Plc has higher upside potential than Johnson & Johnson, analysts believe Royalty Pharma Plc is more attractive than Johnson & Johnson.

Royalty Pharma Plc has a beta of 0.395, which suggesting that the stock is 60.476% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.29%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Johnson & Johnson offers a yield of 2.18% to investors and pays a quarterly dividend of $1.30 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Royalty Pharma Plc's net income of $356M is lower than Johnson & Johnson's net income of $5.1B. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.88x while Johnson & Johnson's PE ratio is 21.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.31x versus 6.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of --. Royalty Pharma Plc's return on equity of 13.52% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Royalty Pharma Plc has a consensus price target of $51.56, signalling upside risk potential of 8.95%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $133.70 which suggests that it could grow by 40.21%. Given that Revolution Medicines, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Revolution Medicines, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.395, which suggesting that the stock is 60.476% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.093%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are larger than Revolution Medicines, Inc. quarterly revenues of --. Royalty Pharma Plc's net income of $356M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.88x while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.31x versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of 57.24% compared to Royalty Pharma Plc's net margin of -1638.53%. Royalty Pharma Plc's return on equity of 13.52% beat Zymeworks, Inc.'s return on equity of -25.56%.

Royalty Pharma Plc has a consensus price target of $51.56, signalling upside risk potential of 8.95%. On the other hand Zymeworks, Inc. has an analysts' consensus of $40.08 which suggests that it could grow by 55.1%. Given that Zymeworks, Inc. has higher upside potential than Royalty Pharma Plc, analysts believe Zymeworks, Inc. is more attractive than Royalty Pharma Plc.

Royalty Pharma Plc has a beta of 0.395, which suggesting that the stock is 60.476% less volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.201, suggesting its more volatile than the S&P 500 by 20.079%.

Royalty Pharma Plc has a quarterly dividend of $0.24 per share corresponding to a yield of 1.94%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Royalty Pharma Plc pays 49.4% of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend. Royalty Pharma Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Royalty Pharma Plc quarterly revenues are $622M, which are larger than Zymeworks, Inc. quarterly revenues of $2.5M. Royalty Pharma Plc's net income of $356M is higher than Zymeworks, Inc.'s net income of -$41.2M. Notably, Royalty Pharma Plc's price-to-earnings ratio is 25.88x while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Royalty Pharma Plc is 10.31x versus 18.55x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.